Credit Suisse and Endeavour led a $115m Series C5 funding round in CeQur.

Credit Suisse Entrepreneur Capital, an investment company, and Endeavour Vision, a private equity firm, led a $115m Series C5 funding round in CeQur, a medical device company. The round was joined by Tandem Diabetes Care, Ypsomed Group, Federated Hermes Kaufmann Funds, Kingdon Capital and GMS Capital, as well as existing investors, Schroder & Co and VI Partners. “We are grateful for the support from this group of world-class investors, who share our vision to transform the lives of people with diabetes who require daily insulin therapy. In the pilot launch of CeQur Simplicity, we’ve been very encouraged by the feedback from healthcare professionals, payers, and people with diabetes, which validates that this novel device offers meaningful benefits to a large segment of people who are insulin dependent. We look forward to advancing our commercial and manufacturing plans in preparation for our broadscale launch,” Bradley Paddock, CeQur President and CEO.